Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 31.00 | |
10 mg | In stock | $ 48.00 | |
25 mg | In stock | $ 85.00 | |
50 mg | In stock | $ 126.00 | |
100 mg | In stock | $ 175.00 | |
200 mg | In stock | $ 315.00 |
Description | Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. |
Targets&IC50 | 5-HT2:3.98 nM(Ki), D2 receptor:14.8 nM(Ki) |
Synonyms | AD-5423 |
Molecular Weight | 367.5 |
Formula | C23H30FN3 |
CAS No. | 132810-10-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 14.29 mg/mL (38.88 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Blonanserin 132810-10-7 GPCR/G Protein Neuroscience Sigma receptor 5-HT Receptor Adrenergic Receptor Dopamine Receptor schizophrenia 5-hydroxytryptamine Receptor antipsychotic AD 5423 excessive sedation Inhibitor Sigma Receptor AD5423 AD-5423 social deficit extrapyramidal symptom hypotension Beta Receptor inhibit Serotonin Receptor inhibitor